A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer

Oral capecitabine is a highly active, well-tolerated and convenient treatment for breast and colorectal cancer. This trial assessed the efficacy and safety of single-agent capecitabine in patients with previously treated ovarian cancer. A total of 29 patients with platinum-pretreated relapsed ovaria...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasey, P A, McMahon, L, Paul, J, Reed, N, Kaye, S B
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394434/
https://www.ncbi.nlm.nih.gov/pubmed/14612890
http://dx.doi.org/10.1038/sj.bjc.6601381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394434/
https://www.ncbi.nlm.nih.gov/pubmed/14612890
http://dx.doi.org/10.1038/sj.bjc.6601381

Ejemplares similares